Advanced search
Publication Cover
Critical Reviews in Clinical Laboratory Sciences Volume 44, 2007 - Issue 1
Submit an article Journal homepage
346
Views
48
CrossRef citations to date
0
Altmetric
Research Article

Clinical Use of Laboratory Tests for the Identification of Secondary Forms of Arterial Hypertension

Gian Paolo Rossi Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
,
Teresa M. Seccia Department of Clinical Methodology and Medical-Surgical Technologies, University of Bari, Bari, Italy
&
Achille C. Pessina Department of Clinical and Experimental Medicine, University of Padova, Padova, Italy
Pages 1-85 | Published online: 10 Oct 2008

REFERENCES

  • Bech K, Hilden T. The frequency of secondary hypertension. Acta Med Scand 1975; 197: 65–69, [INFOTRIEVE], [CSA]
  • Berglund G, Andersson O, Wilhelmsen L. Prevalence of primary and secondary hypertension: studies in a random population sample. Br Med J 1976; 2: 554–556, [INFOTRIEVE], [CSA]
  • Laugesen L P, Hansen A G, Jensen H, Petersen A, Tonnesen K H. The prevalence of secondary hypertension in elderly hypertensive patients. Acta Med Scand Suppl 1983; 676: 161–177, [INFOTRIEVE], [CSA]
  • Dluhy R G. Uncommon forms of secondary hypertension in older patients. Am J Hypertens 1998; 11: 52S–56S, [INFOTRIEVE], [CROSSREF], [CSA]
  • Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 2004; 27: 193–202, [INFOTRIEVE], [CROSSREF], [CSA]
  • Davidson R A, Barri Y M, Wilcox C S. The simplified captopril test: an effective tool to diagnose renovascular hypertension. Am J Kidney Dis 1994; 24: 660–664, [INFOTRIEVE], [CSA]
  • Dal Palu C, Pessina A C, Rossi G P. The diagnostic approach to the hypertensive patient. Contrib Nephrol 1987; 54: 32–37, [INFOTRIEVE], [CSA]
  • Griner P F, Mayewski R J, Mushlin A I, Greenland P. Selection and interpretation of diagnostic tests and procedures. principles and applications. Ann Intern Med 1981; 94: 557–592, [INFOTRIEVE], [CSA]
  • Seccia T M, Rossi G P. Clinical use and pathogenetic basis of laboratory tests for the evaluation of primary arterial hypertension. Crit Rev Clin Lab Sci 2005; 42: 393–452, [INFOTRIEVE], [CROSSREF], [CSA]
  • Conn J W. Part I. Painting background. Part II. Primary aldosteronism, a new clinical syndrome, 1954. J Lab Clin Med 1990; 116: 253–267, [INFOTRIEVE], [CSA]
  • Delcayre C, Swynghedauw B. Molecular mechanisms of myocardial remodeling. The role of aldosterone. J Mol Cell Cardiol 2002; 34: 1577–1584, [INFOTRIEVE], [CROSSREF], [CSA]
  • Rocha R, Funder J W. The pathophysiology of aldosterone in the cardiovascular system. Ann NY Acad Sci 2002; 970: 89–100, [INFOTRIEVE], [CSA]
  • Schmidt B M, Schmieder R E. Aldosterone-induced cardiac damage: focus on blood pressure independent effects. Am J Hypertens 2003; 16: 80–86, [INFOTRIEVE], [CROSSREF], [CSA]
  • Mosso L, Carvajal C, Gonzalez A, Barraza A, Avila F, Montero J, Huete A, Gederlini A, Fardella C E. Primary aldosteronism and hypertensive disease. Hypertension 2003; 42: 161–165, [INFOTRIEVE], [CROSSREF], [CSA]
  • Mulatero P, Stowasser M, Loh K C, Fardella C E, Gordon R D, Mosso L, Gomez-Sanchez C E, Veglio F, Young W F, Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms, in centers from five continents. J Clin Endocrinol Metab 2004; 89: 1045–1050, [INFOTRIEVE], [CROSSREF], [CSA]
  • Rossi G, Boscaro M, Ronconi V, Funder J W. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005; 16: 104–107, [INFOTRIEVE], [CROSSREF], [CSA]
  • Conn J W, Knopf R F, Nesbit R M. Clinical characteristics of primary aldosteronism from an analysis of 145 cases. Am J Surg 1964; 107: 159–172, [INFOTRIEVE], [CROSSREF], [CSA]
  • Conn J W, Cohen E L, Rovner D R, Nesbit R M. Normokalemic primary aldosteronism. a detectable cause of curable “essential” hypertension. JAMA 1965; 193: 200–206, [INFOTRIEVE], [CSA]
  • Conn J W. The evolution of primary aldosteronism: 1954-1967. Harvey Lect 1966; 62: 257–291, [INFOTRIEVE], [CSA]
  • Conn J W, Cohen E L, Rovner D R. Landmark article Oct 19, 1964: Suppression of plasma renin activity in primary aldosteronism. Distinguishing primary from secondary aldosteronism in hypertensive disease. JAMA 1985; 253: 558–566, [INFOTRIEVE], [CROSSREF], [CSA]
  • Gordon R D, Ziesak M D, Tunny T J, Stowasser M, Klemm S A. Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993; 20: 296–298, [INFOTRIEVE], [CSA]
  • Gordon R D, Stowasser M, Tunny T J, Klemm S A, Rutherford J C. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315–318, [INFOTRIEVE], [CSA]
  • Ganguly A. Primary aldosteronism. N Engl J Med 1998; 339: 1828–1834, [INFOTRIEVE], [CROSSREF], [CSA]
  • Loh K C, Koay E S, Khaw M C, Emmanuel S C, Young W F, Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854–2859, [INFOTRIEVE], [CROSSREF], [CSA]
  • Fardella C E, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000; 85: 1863–1867, [INFOTRIEVE], [CROSSREF], [CSA]
  • Rossi G P. Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue?. Curr Hypertens Rep 2004; 6: 1–4, [INFOTRIEVE], [CSA]
  • Rossi G, Bernini G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Mantero F. Prevalence of primary aldosteronism (PA) in newly diagnosed hypertensive patients: Results of a nationwide survey in Italy. J Hypertens 2004; 22: S148, (abst.)[CSA]
  • Rousseau G, Baxter J D, Funder J W, Edelman I S, Tomkins G M. Glucocorticoid and mineralocorticoid receptors for aldosterone. J Steroid Biochem 1972; 3: 219–227, [INFOTRIEVE], [CROSSREF], [CSA]
  • Funder J W, Feldman D, Edelman I S. The roles of plasma binding and receptor specificity in the mineralocorticoid action of aldosterone. Endocrinology 1973; 92: 994–1004, [INFOTRIEVE], [CSA]
  • Pessina A C, Corgnati A, Dal Palu C. Sodium-potassium ratio and electrical potential of colon in the screening of hyperaldosteronism. G Ital Cardiol 1974; 4: 167–172, [INFOTRIEVE], [CSA]
  • Griendling K K, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 2000; 86: 494–501, [INFOTRIEVE], [CSA]
  • Pagano P. NAD(P)H oxidase: marker of the dedifferentiated neointimal smooth muscle cell?. Arterioscler Thromb Vasc Biol 2001; 21: 175–177, [INFOTRIEVE], [CSA]
  • Dluhy R G, Lifton R P. Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 1999; 84: 4341–4344, [INFOTRIEVE], [CROSSREF], [CSA]
  • Seccia T M, Fassina A, Nussdorfer G G, Pessina A C, Rossi G P. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course. Endocr Relat Cancer 2005; 12: 149–159, [INFOTRIEVE], [CROSSREF], [CSA]
  • Haenel L C, Hermayer K L. A case of unilateral adrenal hyperplasia: the diagnostic dilemma of hyperaldosteronism. Endocr Pract 2000; 6: 153–158, [INFOTRIEVE], [CSA]
  • Morioka M, Kobayashi T, Sone A, Furukawa Y, Tanaka H. Primary aldosteronism due to unilateral adrenal hyperplasia: report of two cases and review of the literature. Endocr J 2000; 47: 443–449, [INFOTRIEVE], [CSA]
  • Katayama Y, Takata N, Tamura T, Yamamoto A, Hirata F, Yasuda H, Matsukuma S, Daido Y, Sasano H. A case of primary aldosteronism due to unilateral adrenal hyperplasia. Hypertens Res 2005; 28: 379–384, [INFOTRIEVE], [CROSSREF], [CSA]
  • Hirono Y, Doi M, Yoshimoto T, Kanno K, Himeno Y, Taki K, Sasano H, Hirata Y. A case with primary aldosteronism due to unilateral multiple adrenocortical micronodules. Endocr J 2005; 52: 435–439, [INFOTRIEVE], [CROSSREF], [CSA]
  • Mulatero P, Dluhy R G, Giacchetti G, Boscaro M, Veglio F, Stewart P M. Diagnosis of primary aldosteronism: from screening to subtype differentiation. Trends Endocrinol Metab 2005; 16: 114–119, [INFOTRIEVE], [CROSSREF], [CSA]
  • Stowasser M, Gordon R D, Rutherford J C, Nikwan N Z, Daunt N, Slater G J. Diagnosis and management of primary aldosteronism. J Renin Angiotensin Aldosterone Syst 2001; 2: 156–169, [INFOTRIEVE], [CSA]
  • Rossi G P, Ganzaroli C, Miotto D, De Toni R, Palumbo G, Feltrin G P, Mantero F, Pessina A C. Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. J Hypertens 2006; 24: 371–379, [INFOTRIEVE], [CSA]
  • Kloos R T, Gross M D, Francis I R, Korobkin M, Shapiro B. Incidentally discovered adrenal masses. Endocr Rev 1995; 16: 460–484, [INFOTRIEVE], [CROSSREF], [CSA]
  • Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol 2003; 149: 273–285, [INFOTRIEVE], [CROSSREF], [CSA]
  • Kaplan N M. The current epidemic of primary aldosteronism: causes and consequences. J Hypertens 2004; 22: 863–869, [INFOTRIEVE], [CROSSREF], [CSA]
  • Blumenfeld J D, Laragh J H. Renin system analysis: a rational method for the diagnosis and treatment of the individual patient with hypertension. Am J Hypertens 1998; 11: 894–896, [INFOTRIEVE], [CROSSREF], [CSA]
  • Seiler L, Rump L C, Schulte-Monting J, Slawik M, Borm K, Pavenstadt H, Beuschlein F, Reincke M. Diagnosis of primary aldosteronism: value of different screening parameters and influence of antihypertensive medication. Eur J Endocrinol 2004; 150: 329–337, [INFOTRIEVE], [CROSSREF], [CSA]
  • Sealey J E, Gordon R D, Mantero F. Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab 2005; 16: 86–91, [INFOTRIEVE], [CROSSREF], [CSA]
  • Tanabe A, Naruse M, Takagi S, Tsuchiya K, Imaki T, Takano K. Variability in the renin/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J Clin Endocrinol Metab 2003; 88: 2489–94, [INFOTRIEVE], [CROSSREF], [CSA]
  • Ferrari P, Shaw S G, Nicod J, Saner E, Nussberger J. Active renin versus plasma renin activity to define aldosterone-to-renin ratio for primary aldosteronism. J Hypertens 2004; 22: 377–381, [INFOTRIEVE], [CROSSREF], [CSA]
  • Olivieri O, Ciacciarelli A, Signorelli D, Pizzolo F, Guarini P, Pavan C, Corgnati A, Falcone S, Corrocher R, Micchi A, Cressoni C, Blengio G. Aldosterone to Renin ratio in a primary care setting: the Bussolengo study. J Clin Endocrinol Metab 2004; 89: 4221–4226, [INFOTRIEVE], [CROSSREF], [CSA]
  • Hartman D, Sagnella G A, Chesters C A, Macgregor G A. Direct renin assay and plasma renin activity assay compared. Clin Chem 2004; 50: 2159–2161, [INFOTRIEVE], [CSA]
  • Bizollon C A, Riviere J F, Franchimont P, Faure A, Claustrat B. Solid phase radioimmunoassay of plasma aldosterone. Steroids 1974; 23: 809–821, [INFOTRIEVE], [CSA]
  • Lijnen P, Amery A, Fagard R, Corvol P. Direct radioimmunoassay of plasma aldosterone in normal subjects. Clin Chim Acta 1978; 84: 305–314, [INFOTRIEVE], [CROSSREF], [CSA]
  • Katz F H, Romfh P, Smith J A. Diurnal variation of plasma aldosterone, cortisol and renin activity in supine man. J Clin Endocrinol Metab 1975; 40: 125–134, [INFOTRIEVE], [CSA]
  • Perschel F H, Schemer R, Seiler L, Reincke M, Deinum J, Maser-Gluth C, Mechelhoff D, Tauber R, Diederich S. Rapid screening test for primary hyperaldosteronism: ratio of plasma aldosterone to renin concentration determined by fully automated chemiluminescence immunoassays. Clin Chem 2004; 50: 1650–1655, [INFOTRIEVE], [CROSSREF], [CSA]
  • Stabler T V, Siegel A L. Chemiluminescence immunoassay of aldosterone in serum. Clin Chem 1991; 37: 1987–1989, [INFOTRIEVE], [CSA]
  • Atherden S M, Corrie J E, Jones D B, Al Dujaili E A, Edwards C R. Development and application of a direct radioimmunoassay for aldosterone in saliva. Steroids 1985; 46: 845–55, [INFOTRIEVE], [CROSSREF], [CSA]
  • Few J D, Unwin R J, Carmichael D J, James V H. Diurnal fluctuation in saliva aldosterone concentration. J Steroid Biochem 1987; 26: 265–271, [INFOTRIEVE], [CROSSREF], [CSA]
  • Vecsei P, Penke B, Joumaah A. Radioimmunoassay of free aldosterone and of its 18-oxo-glucuronide in human urine. Experientia 1972; 28: 622–624, [INFOTRIEVE], [CROSSREF], [CSA]
  • Gomez-Sanchez C E, Holland O B. Urinary tetrahydroaldosterone and aldosterone-18-glucuronide excretion in white and black normal subjects and hypertensive patients. J Clin Endocrinol Metab 1981; 52: 214–219, [INFOTRIEVE], [CSA]
  • Ishida J, Sonezaki S, Yamaguchi M, Yoshitake T. High-performance liquid chromatographic determination of 3 alpha, 5 beta-tetrahydroaldosterone in human urine with chemiluminescence detection. Analyst 1992; 117: 1719–1724, [INFOTRIEVE], [CROSSREF], [CSA]
  • Mattingly D, Martin H, Tyler C M. Estimation of urinary aldosterone using thin-layer chromatography and fluorimetry. J Clin Pathol 1993; 46: 1109–1112, [INFOTRIEVE], [CSA]
  • Cunningham S K, Sequeira S J, Chambers J, Heffernan A, McKenna T J. Optimisation of total urinary aldosterone estimation: comparison with other laboratory methods for assessment of mineralocorticoid status. J Steroid Biochem 1988; 31: 125–130, [INFOTRIEVE], [CROSSREF], [CSA]
  • Few J D, Wallis P J, James V H. The relationship between salivary aldosterone and plasma free aldosterone concentrations. Clin Endocrinol (Oxf) 1986; 24: 119–126, [CSA]
  • Stowasser M, Gordon R D. The aldosterone-renin ratio and primary aldosteronism. Mayo Clin Proc 2002; 77: 202–203, [INFOTRIEVE], [CSA]
  • Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 2002; 40: 897–902, [INFOTRIEVE], [CROSSREF], [CSA]
  • Gordon R D. Primary aldosteronism. J Endocrinol Invest 1995; 18: 495–511, [INFOTRIEVE], [CSA]
  • Fiad T M, Cunningham S K, Hayes F J, McKenna T J. Effects of nifedipine treatment on the renin-angiotensin-aldosterone axis. J Clin Endocrinol Metab 1997; 82: 457–460, [INFOTRIEVE], [CROSSREF], [CSA]
  • Lyons D F, Kem D C, Brown R D, Hanson C S, Carollo M L. Single dose captopril as a diagnostic test for primary aldosteronism. J Clin Endocrinol Metab 1983; 57: 892–896, [INFOTRIEVE], [CSA]
  • Racine M C, Douville P, Lebel M. Functional tests for primary aldosteronism: value of captopril suppression. Curr Hypertens Rep 2002; 4: 245–249, [INFOTRIEVE], [CSA]
  • Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 2002; 15: 896–902, [INFOTRIEVE], [CROSSREF], [CSA]
  • Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 2006; 24: 737–745, [INFOTRIEVE], [CSA]
  • Iwaoka T, Umeda T, Naomi S, Inoue J, Sasaki M, Yamauchi J, Sato T. The usefulness of the captopril test as a simultaneous screening for primary aldosteronism and renovascular hypertension. Am J Hypertens 1993; 6: 899–906, [INFOTRIEVE], [CSA]
  • Hambling C, Jung R T, Gunn A, Browning M C, Bartlett W A. Re-evaluation of the captopril test for the diagnosis of primary hyperaldosteronism. Clin Endocrinol (Oxf) 1992; 36: 499–503, [CSA]
  • Agharazii M, Douville P, Grose J H, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 2001; 37: 1440–1443, [INFOTRIEVE], [CSA]
  • Rossi G P, Rossi E, Pavan E, Rosati N, Zecchel R, Semplicini A, Perazzoli F, Pessina A C. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf) 1998; 49: 713–723, [CROSSREF], [CSA]
  • Lim P O, Dow E, Brennan G, Jung R T, MacDonald T M. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311–315, [INFOTRIEVE], [CROSSREF], [CSA]
  • Holland O B, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez C E. Further evaluation of saline infusion for the diagnosis of primary aldosteronism. Hypertension 1984; 6: 717–23, [INFOTRIEVE], [CSA]
  • Young W F, Jr. Primary aldosteronism: management issues. Ann NY Acad Sci 2002; 970: 61–76, [INFOTRIEVE], [CSA]
  • Mayo-Smith W W, Boland G W, Noto R B, Lee M J. State-of-the-art adrenal imaging. Radiographics 2001; 21: 995–1012, [INFOTRIEVE], [CSA]
  • Lockhart M E, Smith J K, Kenney P J. Imaging of adrenal masses. Eur J Radiol 2002; 41: 95–112, [INFOTRIEVE], [CROSSREF], [CSA]
  • Blake M A, Kalra M K, Maher M M, Sahani D V, Sweeney A T, Mueller P R, Hahn P F, Boland G W. Pheochromocytoma: an imaging chameleon. Radiographics 2004; 24(Suppl 1)S87–S99, [INFOTRIEVE], [CSA]
  • Sahdev A, Reznek R H. Imaging evaluation of the non-functioning indeterminate adrenal mass. Trends Endocrinol Metab 2004; 15: 271–276, [INFOTRIEVE], [CROSSREF], [CSA]
  • Renken N S, Krestin G P. Magnetic resonance imaging of the adrenal glands. Semin Ultrasound CT MR 2005; 26: 162–171, [INFOTRIEVE], [CROSSREF], [CSA]
  • Rossi G P, Chiesura-Corona M, Tregnaghi A, Zanin L, Perale R, Soattin S, Pelizzo M R, Feltrin G P, Pessina A C. Imaging of aldosterone-secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary aldosteronism. J Hum Hypertens 1993; 7: 357–363, [INFOTRIEVE], [CSA]
  • Magill S B, Raff H, Shaker J L, Brickner R C, Knechtges T E, Kehoe M E, Findling J W. Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 2001; 86: 1066–1071, [INFOTRIEVE], [CROSSREF], [CSA]
  • Gross M D, Shapiro B, Freitas J E. Limited significance of asymmetric adrenal visualization on dexamethasone-suppression scintigraphy. J Nucl Med 1985; 26: 43–48, [INFOTRIEVE], [CSA]
  • Vetter H, Fischer M, Galanski M, Stieber U, Tenschert W, Baumgart P, Winterberg B, Vetter W. Primary aldosteronism: diagnosis and noninvasive lateralization procedures. Cardiology 1985; 72(Suppl 1)57–63, [INFOTRIEVE], [CSA]
  • Mansoor G A, Malchoff C D, Arici M H, Karimeddini M K, Whalen G F. Unilateral adrenal hyperplasia causing primary aldosteronism: limitations of I-131 norcholesterol scanning. Am J Hypertens 2002; 15: 459–464, [INFOTRIEVE], [CROSSREF], [CSA]
  • Lumachi F, Marzola M C, Zucchetta P, Tregnaghi A, Cecchin D, Favia G, Bui F. Non-invasive adrenal imaging in primary aldosteronism. Sensitivity and positive predictive value of radiocholesterol scintigraphy, CT scan and MRI. Nucl Med Commun 2003; 24: 683–688, [INFOTRIEVE], [CROSSREF], [CSA]
  • Rossi G P, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin G P, Pessina A C. Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001; 86: 1083–1090, [INFOTRIEVE], [CROSSREF], [CSA]
  • Daunt N. Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 2005; 25(Suppl 1)S143–S158, [INFOTRIEVE], [CSA]
  • Young W F, Jr., Stanson A W, Grant C S, Thompson G B, Van Heerden J A. Primary aldosteronism: adrenal venous sampling. Surgery 1996; 120: 913–919, [INFOTRIEVE], [CROSSREF], [CSA]
  • Phillips J L, Walther M M, Pezzullo J C, Rayford W, Choyke P L, Berman A A, Linehan W M, Doppman J L, Gill J J, Jr. Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab 2000; 85: 4526–33, [INFOTRIEVE], [CROSSREF], [CSA]
  • Stowasser M, Gordon R D, Gunasekera T G, Cowley D C, Ward G, Archibald C, Smithers B M. High rate of detection of primary aldosteronism, including surgically treatable forms, after “non-selective” screening of hypertensive patients. J Hypertens 2003; 21: 2149–57, [INFOTRIEVE], [CROSSREF], [CSA]
  • Bravo E L, Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 2003; 24: 539–553, [INFOTRIEVE], [CROSSREF], [CSA]
  • Beard C M, Sheps S G, Kurland L T, Carney J A, Lie J T. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 1983; 58: 802–804, [INFOTRIEVE], [CSA]
  • Stenstrom G, Svardsudd K. Pheochromocytoma in Sweden 1958–1981. An analysis of the National Cancer Registry Data. Acta Med Scand 1986; 220: 225–232, [INFOTRIEVE], [CSA]
  • Smythe G A, Edwards G, Graham P, Lazarus L. Biochemical diagnosis of pheochromocytoma by simultaneous measurement of urinary excretion of epinephrine and norepinephrine. Clin Chem 1992; 38: 486–492, [INFOTRIEVE], [CSA]
  • Kudva Y C, Sawka A M, Young W F, Jr. Clinical review 164: The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 2003; 88: 4533–4539, [INFOTRIEVE], [CROSSREF], [CSA]
  • Mantero F, Terzolo M, Arnaldi G, Osella G, Masini A M, Ali A, Giovagnetti M, Opocher G, Angeli A. A survey on adrenal incidentaloma in Italy. Study group on adrenal tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000; 85: 637–644, [INFOTRIEVE], [CROSSREF], [CSA]
  • McNeil A R, Blok B H, Koelmeyer T D, Burke M P, Hilton J M. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust NZ J Med 2000; 30: 648–652, [CSA]
  • Manger W M, Eisenhofer G. Pheochromocytoma: diagnosis and management update. Curr Hypertens Rep 2004; 6: 477–484, [INFOTRIEVE], [CSA]
  • Bravo E L. Pheochromocytoma: an approach to antihypertensive management. Ann NY Acad Sci 2002; 970: 1–10, [INFOTRIEVE], [CSA]
  • Dluhy R G, Lawrence J E, Williams G H. Endocrine hypertension. Williams Textbook of Endocrinology, 10th Ed., P R Larsen, H M Kronenberg, S Melmed, K S Polonski. Saunders, Philadelphia 2003; 552–586
  • Crout J R, Sjoerdsma A. Turnover and metabolism of catecholamines in patients with pheochromocytoma. J Clin Invest 1964; 43: 94–102, [INFOTRIEVE], [CSA]
  • Bravo E L, Tarazi R C, Gifford R W, Stewart B H. Circulating and urinary catecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 1979; 301: 682–686, [INFOTRIEVE], [CSA]
  • Page L B, Raker J W, Berberich F R. Pheochromocytoma with predominant epinephrine secretion. Am J Med 1969; 47: 648–652, [INFOTRIEVE], [CROSSREF], [CSA]
  • Zanin L, Rossi G, Poletti A, Piotto A, Chiesura-Corona M, Pessina A C. Necrosis of a phaeochromocytoma associated with spontaneous remission of diabetes and hypertension. Clin Endocrinol (Oxf) 1993; 39: 613–617, [CSA]
  • Bravo E L, Tarazi R C, Fouad F M, Textor S C, Gifford R W, Jr., Vidt D G. Blood pressure regulation in pheochromocytoma. Hypertension 1982; 4: 193–199, [INFOTRIEVE], [CSA]
  • Johnson M D, Smith P G, Mills E, Schanberg S M. Paradoxical elevation of sympathetic activity during catecholamine infusion in rats. J Pharmacol Exp Ther 1983; 227: 254–259, [INFOTRIEVE], [CSA]
  • Prokocimer P G, Maze M, Hoffman B B. Role of the sympathetic nervous system in the maintenance of hypertension in rats harboring pheochromocytoma. J Pharmacol Exp Ther 1987; 241: 870–874, [INFOTRIEVE], [CSA]
  • Tsujimoto G, Honda K, Hoffman B B, Hashimoto K. Desensitization of postjunctional alpha 1-and alpha 2-adrenergic receptor-mediated vasopressor responses in rat harboring pheochromocytoma. Circ Res 1987; 61: 86–98, [INFOTRIEVE], [CSA]
  • Langer S Z, Cavero I, Massingham R. Recent developments in noradrenergic neurotransmission and its relevance to the mechanism of action of certain antihypertensive agents. Hypertension 1980; 2: 372–382, [INFOTRIEVE], [CSA]
  • Grassi G, Seravalle G, Turri C, Mancia G. Sympathetic nerve traffic responses to surgical removal of pheochromocytoma. Hypertension 1999; 34: 461–465, [INFOTRIEVE], [CSA]
  • Massart P E, Hodeige D, Donckier J. Adrenomedullin: view on a novel vasodilatory peptide with natriuretic properties. Acta Cardiol 1996; 51: 259–269, [INFOTRIEVE], [CSA]
  • Khan A I, Kato J, Kitamura K, Kangawa K, Eto T. Hypotensive effect of chronically infused adrenomedullin in conscious Wistar-Kyoto and spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1997; 24: 139–142, [INFOTRIEVE], [CSA]
  • Hsiao R J, Parmer R J, Takiyyuddin M A, O'Connor D T. Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma. Medicine (Baltimore) 1991; 70: 33–45, [CSA]
  • Bravo E L, Gifford R W, Jr. Current concepts. Pheochromocytoma: diagnosis, localization and management. N Engl J Med 1984; 311: 1298–303, [INFOTRIEVE], [CSA]
  • Neumann H P, Berger D P, Sigmund G, Blum U, Schmidt D, Parmer R J, Volk B, Kirste G. Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 1993; 329: 1531–1538, [INFOTRIEVE], [CROSSREF], [CSA]
  • Evans D B, Lee J E, Merrell R C, Hickey R C. Adrenal medullary disease in multiple endocrine neoplasia type 2. Appropriate management. Endocrinol Metab Clin North Am 1994; 23: 167–76, [INFOTRIEVE], [CSA]
  • Hoff A O, Cote G J, Gagel R F. Multiple endocrine neoplasias. Annu Rev Physiol 2000; 62: 377–411, [INFOTRIEVE], [CROSSREF], [CSA]
  • Walther M M, Herring J, Enquist E, Keiser H R, Linehan W M. von Recklinghausen's disease and pheochromocytomas. J Urol 1999; 162: 1582–1586, [INFOTRIEVE], [CROSSREF], [CSA]
  • Rossi G, Deppieri O, Pessina A C. Effect of haemolysis on high-performance liquid chromatography measurements of free plasma catecholamines. J Chromatogr 1986; 380: 117–121, [INFOTRIEVE], [CSA]
  • Lenders J W, Pacak K, Walther M M, Linehan W M, Mannelli M, Friberg P, Keiser H R, Goldstein D S, Eisenhofer G. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA 2002; 287: 1427–1434, [INFOTRIEVE], [CROSSREF], [CSA]
  • Gagel R F, Tashjian A H, Jr., Cummings T, Papathanasopoulos N, Kaplan M M, DeLellis R A, Wolfe H J, Reichlin S. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 1988; 318: 478–484, [INFOTRIEVE], [CSA]
  • Eisenhofer G, Walther M, Keiser H R, Lenders J W, Friberg P, Pacak K. Plasma metanephrines: a novel and cost-effective test for pheochromocytoma. Braz J Med Biol Res 2000; 33: 1157–1169, [INFOTRIEVE], [CROSSREF], [CSA]
  • Lenders J W, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet 2005; 366: 665–675, [INFOTRIEVE], [CROSSREF], [CSA]
  • Lenders J W, Keiser H R, Goldstein D S, Willemsen J J, Friberg P, Jacobs M C, Kloppenborg P W, Thien T, Eisenhofer G. Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med 1995; 123: 101–109, [INFOTRIEVE], [CSA]
  • Raber W, Raffesberg W, Bischof M, Scheuba C, Niederle B, Gasic S, Waldhausl W, Roden M. Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 2000; 160: 2957–2963, [INFOTRIEVE], [CROSSREF], [CSA]
  • Dal Palu C, Pessina A C, Semplicini A, Hlede M, Morandin F, Palatini P, Sperti G, Rossi G P. Intravenous labetalol in severe hypertension. Br J Clin Pharmacol 1982; 13: 97S–99S, [INFOTRIEVE], [CSA]
  • Feldman J M. Falsely elevated urinary excretion of catecholamines and metanephrines in patients receiving labetalol therapy. J Clin Pharmacol 1987; 27: 288–292, [INFOTRIEVE], [CSA]
  • Cook F J, Chandler D W, Snyder D K. Effect of buspirone on urinary catecholamine assays. N Engl J Med 1995; 332: 401, [INFOTRIEVE], [CROSSREF], [CSA]
  • O'Connor D T, Frigon R P. Chromogranin A, the major catecholamine storage vesicle soluble protein. Multiple size forms, subcellular storage, and regional distribution in chromaffin and nervous tissue elucidated by radioimmunoassay. J Biol Chem 1984; 259: 3237–3247, [INFOTRIEVE], [CSA]
  • O'Connor D T, Deftos L J. Secretion of chromogranin A by peptide-producing endocrine neoplasms. N Engl J Med 1986; 314: 1145–1151, [INFOTRIEVE], [CSA]
  • Parmer R J, Xi X P, Wu H J, Helman L J, Petz L N. Secretory protein traffic. Chromogranin A contains a dominant targeting signal for the regulated pathway. J Clin Invest 1993; 92: 1042–1054, [INFOTRIEVE], [CSA]
  • Aardal S, Aardal N P, Larsen T H, Angeletti R H, Stridsberg M, Taupenot L, Aunis D, Helle K B. Human pheochromocytoma: different patterns of catecholamines and chromogranins in the intact tumour, urine and serum in clinically unsuspected cases. Scand J Clin Lab Invest 1996; 56: 511–523, [INFOTRIEVE], [CSA]
  • Rao F, Keiser H R, O'Connor D T. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension 2000; 36: 1045–1052, [INFOTRIEVE], [CSA]
  • Rao F, Keiser H R, O'Connor D T. Malignant and benign pheochromocytoma: chromaffin granule transmitters and the response to medical and surgical treatment. Ann NY Acad Sci 2002; 971(530-2)530–532, [INFOTRIEVE], [CSA]
  • Canale M P, Bravo E L. Diagnostic specificity of serum chromogranin-A for pheochromocytoma in patients with renal dysfunction. J Clin Endocrinol Metab 1994; 78: 1139–1144, [INFOTRIEVE], [CROSSREF], [CSA]
  • Nishikimi T, Kitamura K, Saito Y, Shimada K, Ishimitsu T, Takamiya M, Kangawa K, Matsuo H, Eto T, Omae T. Clinical studies on the sites of production and clearance of circulating adrenomedullin in human subjects. Hypertension 1994; 24: 600–604, [INFOTRIEVE], [CSA]
  • Ishimitsu T, Nishikimi T, Saito Y, Kitamura K, Eto T, Kangawa K, Matsuo H, Omae T, Matsuoka H. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994; 94: 2158–2161, [INFOTRIEVE], [CSA]
  • Letizia C, De Toma G, Caliumi C, Cerci S, Massa R, Loria R D, Alo P, Marinoni E M, Diacinti D, D'Erasmo E. Plasma adrenomedullin concentrations in patients with adrenal pheochromocytoma. Horm Metab Res 2001; 33: 290–294, [INFOTRIEVE], [CROSSREF], [CSA]
  • Lawrence A M. Glucagon provocative test for pheochromocytoma. Ann Intern Med 1967; 66: 1091–1096, [INFOTRIEVE], [CSA]
  • Bravo E L, Tarazi R C, Fouad F M, Vidt D G, Gifford R W, Jr. Clonidine-suppression test: a useful aid in the diagnosis of pheochromocytoma. N Engl J Med 1981; 305: 623–626, [INFOTRIEVE], [CSA]
  • Bravo E L. Primary aldosteronism. Issues in diagnosis and management. Endocrinol Metab Clin North Am 1994; 23: 271–283, [INFOTRIEVE], [CSA]
  • Donis-Keller H, Dou S, Chi D, Carlson K M, Toshima K, Lairmore T C, Howe J R, Moley J F, Goodfellow P, Wells S A, Jr. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993; 2: 851–856, [INFOTRIEVE], [CSA]
  • Mulligan L M, Kwok J B, Healey C S, Elsdon M J, Eng C, Gardner E, Love D R, Mole S E, Moore J K, Papi L. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993; 363: 458–460, [INFOTRIEVE], [CROSSREF], [CSA]
  • Neumann H P, Eng C, Mulligan L M, Glavac D, Zauner I, Ponder B A, Crossey P A, Maher E R, Brauch H. Consequences of direct genetic testing for germline mutations in the clinical management of families with multiple endocrine neoplasia, type II. JAMA 1995; 274: 1149–1151, [INFOTRIEVE], [CROSSREF], [CSA]
  • Eng C. Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med 1996; 335: 943–951, [INFOTRIEVE], [CROSSREF], [CSA]
  • Baysal B E, Ferrell R E, Willett-Brozick J E, Lawrence E C, Myssiorek D, Bosch A, van der M A, Taschner P E, Rubinstein W S, Myers E N, Richard C W, III, Cornelisse C J, Devilee P, Devlin B. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000; 287: 848–851, [INFOTRIEVE], [CROSSREF], [CSA]
  • Astuti D, Douglas F, Lennard T W, Aligianis I A, Woodward E R, Evans D G, Eng C, Latif F, Maher E R. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001; 357: 1181–1182, [INFOTRIEVE], [CROSSREF], [CSA]
  • Neumann H P, et al, Freiburg-Warsaw-Columbus Pheochromocytoma Study Group. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 2002; 346: 1459–1466, [INFOTRIEVE], [CROSSREF], [CSA]
  • Schiavi F, et al, European-American Paraganglioma Study Group. Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene. JAMA 2005; 294: 2057–2063, [INFOTRIEVE], [CSA]
  • Lairmore T C, Ball D W, Baylin S B, Wells S A, Jr. Management of pheochromocytomas in patients with multiple endocrine neoplasia type 2 syndromes. Ann Surg 1993; 217: 595–601, [INFOTRIEVE], [CSA]
  • Aprill B S, Drake A J, III, Lasseter D H, Shakir K M. Silent adrenal nodules in von Hippel-Lindau disease suggest pheochromocytoma. Ann Intern Med 1994; 120: 485–487, [INFOTRIEVE], [CSA]
  • Lee J E, Curley S A, Gagel R F, Evans D B, Hickey R C. Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 1996; 120: 1064–1070, [INFOTRIEVE], [CROSSREF], [CSA]
  • Arnaldi G, Masini A M, Giacchetti G, Taccaliti A, Faloia E, Mantero F. Adrenal incidentaloma. Braz J Med Biol Res 2000; 33: 1177–1189, [INFOTRIEVE], [CROSSREF], [CSA]
  • Whalen R K, Althausen A F, Daniels G H. Extra-adrenal pheochromocytoma. J Urol 1992; 147: 1–10, [INFOTRIEVE], [CSA]
  • Bravo E L. Pheochromocytoma: new concepts and future trends. Kidney Int 1991; 40: 544–556, [INFOTRIEVE], [CSA]
  • Remine W H, Chong G C, Van Heerden J A, Sheps S G, Harrison E G, Jr. Current management of pheochromocytoma. Ann Surg 1974; 179: 740–748, [INFOTRIEVE], [CROSSREF], [CSA]
  • Nativ O, Grant C S, Sheps S G, O'Fallon J R, Farrow G M, Van Heerden J A, Lieber M M. The clinical significance of nuclear DNA ploidy pattern in 184 patients with pheochromocytoma. Cancer 1992; 69: 2683–2687, [INFOTRIEVE], [CROSSREF], [CSA]
  • Helman L J, Cohen P S, Averbuch S D, Cooper M J, Keiser H R, Israel M A. Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol 1989; 7: 1720–1725, [INFOTRIEVE], [CSA]
  • Salmenkivi K, Arola J, Voutilainen R, Ilvesmaki V, Haglund C, Kahri A I, Heikkila P, Liu J. Inhibin/activin betaB-subunit expression in pheochromocytomas favors benign diagnosis. J Clin Endocrinol Metab 2001; 86: 2231–2235, [INFOTRIEVE], [CROSSREF], [CSA]
  • deS S P, Denker J, Bravo E L, Graham R M. Production, characterization, and expression of neuropeptide Y by human pheochromocytoma. J Clin Invest 1995; 96: 2503–2509, [CSA]
  • Alcazar J M, Rodicio J L. How to handle renovascular hypertension. J Hypertens 2001; 19: 2109–2111, [INFOTRIEVE], [CROSSREF], [CSA]
  • Pickering T G. The role of laboratory testing in the diagnosis of renovascular hypertension. Clin Chem 1991; 37: 1831–1837, [INFOTRIEVE], [CSA]
  • Carmichael P, Carmichael A R. Atherosclerotic renal artery stenosis: from diagnosis to treatment. Postgrad Med J 1999; 75: 527–536, [INFOTRIEVE], [CSA]
  • Derkx F H, Schalekamp M A. Renal artery stenosis and hypertension. Lancet 1994; 344: 237–239, [INFOTRIEVE], [CROSSREF], [CSA]
  • Helin K H, Tikkanen I, von Knorring J E, Lepantalo M J, Liewendahl B K, Laasonen L S, Fyhrquist F Y, Tikkanen T. Screening for renovascular hypertension in a population with relatively low prevalence. J Hypertens 1998; 16: 1523–1529, [INFOTRIEVE], [CROSSREF], [CSA]
  • Eardley K S, Lipkin G W. Atherosclerotic renal artery stenosis: is it worth diagnosing?. J Hum Hypertens 1999; 13: 217–220, [INFOTRIEVE], [CROSSREF], [CSA]
  • Vasbinder G B, Nelemans P J, Kessels A G, Kroon A A, de Leeuw P W, van Engelshoven J M. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med 2001; 135: 401–411, [INFOTRIEVE], [CSA]
  • Rossi G P, Pavan E, Chiesura-Corona M, Bader M, Paganini G, Cesari M, De Toni R, Feltrin G P, Ganten D, Pessina A C. Renovascular hypertension with low-to-normal plasma renin: clinical and angiographic features. Clin Sci (Lond) 1997; 93: 435–443, [CSA]
  • Krijnen P, van Jaarsveld B C, Steyerberg E W, Man in't Veld A J, Schalekamp M A, Habbema J D. A clinical prediction rule for renal artery stenosis. Ann Intern Med 1998; 129: 705–711, [INFOTRIEVE], [CSA]
  • Textor S C. Epidemiology and clinical presentation. Semin Nephrol 2000; 20: 426–431, [INFOTRIEVE], [CSA]
  • Safian R D, Textor S C. Renal-artery stenosis. N Engl J Med 2001; 344: 431–442, [INFOTRIEVE], [CROSSREF], [CSA]
  • Preston R A, Epstein M. Ischemic renal disease: an emerging cause of chronic renal failure and end-stage renal disease. J Hypertens 1997; 15: 1365–1377, [INFOTRIEVE], [CROSSREF], [CSA]
  • Chiesura-Corona M, Feltrin G P, Savastano S, Miotto D, Torraco A, Castellan L, Rossi G P. Excess prevalence of supraaortic artery lesions in renovascular hypertension: an arteriographic study. Cardiovasc Intervent Radiol 1994; 17: 264–270, [INFOTRIEVE], [CROSSREF], [CSA]
  • Rossi G P, Rossi A, Zanin L, Calabro A, Feltrin G P, Pessina A C, Crepaldi G, Dal Palu C. Excess prevalence of extracranial carotid artery lesions in renovascular hypertension. Am J Hypertens 1992; 5: 8–15, [INFOTRIEVE], [CSA]
  • Harding M B, Smith L R, Himmelstein S I, Harrison K, Phillips H R, Schwab S J, Hermiller J B, Davidson C J, Bashore T M. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol 1992; 2: 1608–1616, [INFOTRIEVE], [CSA]
  • Choudhri A H, Cleland J G, Rowlands P C, Tran T L, McCarty M, al Kutoubi M A. Unsuspected renal artery stenosis in peripheral vascular disease. BMJ 1990; 301: 1197–1198, [INFOTRIEVE], [CSA]
  • Zierler R E, Bergelin R O, Isaacson J A, Strandness D E, Jr. Natural history of atherosclerotic renal artery stenosis: a prospective study with duplex ultrasonography. J Vasc Surg 1994; 19: 250–257, [INFOTRIEVE], [CSA]
  • Caps M T, Zierler R E, Polissar N L, Bergelin R O, Beach K W, Cantwell-Gab K, Casadei A, Davidson R C, Strandness D E, Jr. Risk of atrophy in kidneys with atherosclerotic renal artery stenosis. Kidney Int 1998; 53: 735–742, [INFOTRIEVE], [CROSSREF], [CSA]
  • Olin J W, Melia M, Young J R, Graor R A, Risius B. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med 1990; 88: 46N–51N, [INFOTRIEVE], [CROSSREF], [CSA]
  • Aurell M. Screening for secondary hypertension. Curr Hypertens Rep 1999; 1: 461, [INFOTRIEVE], [CSA]
  • Maxwell M H, Bleifer K H, Franklin S S, Varady P D. Cooperative study of renovascular hypertension. Demographic analysis of the study. JAMA 1972; 220: 1195–1204, [INFOTRIEVE], [CROSSREF], [CSA]
  • Svetkey L P, Helms M J, Dunnick N R, Klotman P E. Clinical characteristics useful in screening for renovascular disease. South Med J 1990; 83: 743–747, [INFOTRIEVE], [CSA]
  • Textor S C. Pathophysiology of renal failure in renovascular disease. Am J Kidney Dis 1994; 24: 642–651, [INFOTRIEVE], [CSA]
  • Rundback J H, Sacks D, Kent K C, Cooper C, Jones D, Murphy T, Rosenfield K, White C, Bettmann M, Cortell S, Puschett J, Clair D, Cole P. Guidelines for the reporting of renal artery revascularization in clinical trials. American Heart Association. Circulation 2002; 106: 1572–1585, [INFOTRIEVE], [CROSSREF], [CSA]
  • de Leeuw P W. On the significance of renal vein renins in renovascular hypertension. J Hypertens 2002; 20: 843–845, [INFOTRIEVE], [CROSSREF], [CSA]
  • Vaughan E D, Jr., Buhler F R, Laragh J H, Sealey J E, Baer L, Bard R H. Renovascular hypertension: renin measurements to indicate hypersecretion and contralateral suppression, estimate renal plasma flow, and score for surgical curability. Am J Med 1973; 55: 402–414, [INFOTRIEVE], [CROSSREF], [CSA]
  • Vaughan E D, Jr., Carey R M, Ayers C R, Peach M J, Tegtmeyer C J, Wellons H A, Jr. Physiologic definition of blood pressure response to renal revascularization in patients with renovascular hypertension. Kidney Int Suppl 1979; S83–S92, [CSA]
  • Muller F B, Sealey J E, Case D B, Atlas S A, Pickering T G, Pecker M S, Preibisz J J, Laragh J H. The captopril test for identifying renovascular disease in hypertensive patients. Am J Med 1986; 80: 633–644, [INFOTRIEVE], [CROSSREF], [CSA]
  • Postma C T, van der Steen P H, Hoefnagels W H, de Boo T, Thien T. The captopril test in the detection of renovascular disease in hypertensive patients. Arch Intern Med 1990; 150: 625–628, [INFOTRIEVE], [CROSSREF], [CSA]
  • Svetkey L P, Wilkinson R, Jr., Dunnick N R, Smith S R, Dunham C B, Lambert M, Klotman P E. Captopril renography in the diagnosis of renovascular disease. Am J Hypertens 1991; 4: 711S–715S, [INFOTRIEVE], [CSA]
  • Stephan D, Welsch M, Decker N, Brule J M, Jahn C, Grima M, Imbs J L. Captopril test for detecting renal artery stenosis: changes in plasma renin concentration. Arch Mal Coeur Vaiss 1993; 86: 1249–1252, [INFOTRIEVE], [CSA]
  • Schreij G, van Es P N, Schiffers P M, Lavrijssen A T, de Leeuw P W. ‘Captopril test’, with blood pressure and peripheral renin as response variables in hypertensive patients with suspected renal artery stenosis. J Hum Hypertens 1995; 9: 741–746, [INFOTRIEVE], [CSA]
  • Dondi M, Levorato M, Corbelli C, Zagni P, Zuccala A, Gaggi R, Marchetta F, Losinno F, Stella A, Mirelli M. Detection of renal artery stenosis by means of captopril renography with 99mTc-DTPA. Contrib Nephrol 1990; 79: 181–185, [INFOTRIEVE], [CSA]
  • Mann S J, Pickering T G, Sos T A, Uzzo R G, Sarkar S, Friend K, Rackson M E, Laragh J H. Captopril renography in the diagnosis of renal artery stenosis: accuracy and limitations. Am J Med 1991; 90: 30–40, [INFOTRIEVE], [CROSSREF], [CSA]
  • Nitzsche E, Grosser G, Rump C, Strauss E, Meyer E, Keller E, Moser E. Captopril-renal function scintigraphy in the clarification of arterial hypertension. Radiologe 1991; 31: 141–146, [INFOTRIEVE], [CSA]
  • Setaro J F, Chen C C, Hoffer P B, Black H R. Captopril renography in the diagnosis of renal artery stenosis and the prediction of improvement with revascularization. The Yale Vascular Center experience. Am J Hypertens 1991; 4: 698S–705S, [INFOTRIEVE], [CSA]
  • Dondi M, Fanti S, Barozzi L, De Fabritiis A, Losinno F, Pavlica P, Monetti N, Zuccala A. Evaluation by captopril renal scintigraphy and echo-Doppler flowmetry of hypertensive patients at high risk for renal artery stenosis. J Nucl Biol Med 1992; 36: 309–314, [INFOTRIEVE], [CSA]
  • Fommei E, Ghione S, Hilson A J, Mezzasalma L, Oei H Y, Piepsz A, Volterrani D. Captopril radionuclide test in renovascular hypertension: a European multicentre study. European Multicentre Study Group. Eur J Nucl Med 1993; 20: 617–623, [INFOTRIEVE], [CROSSREF], [CSA]
  • Kahn D, Ben Haim S, Bushnell D L, Madsen M T, Kirchner P T. Captopril-enhanced 99Tcm-MAG3 renal scintigraphy in subjects with suspected renovascular hypertension. Nucl Med Commun 1994; 15: 515–528, [INFOTRIEVE], [CSA]
  • Mittal B R, Kumar P, Arora P, Kher V, Singhal M K, Maini A, Das B K. Role of captopril renography in the diagnosis of renovascular hypertension. Am J Kidney Dis 1996; 28: 209–213, [INFOTRIEVE], [CSA]
  • Pedersen E B, Egeblad M, Jorgensen J, Nielsen S S, Spencer E S, Rehling M. Diagnosing renal artery stenosis: a comparison between conventional renography, captopril renography and ultrasound Doppler in a large consecutive series of patients with arterial hypertension. Blood Press 1996; 5: 342–348, [INFOTRIEVE], [CSA]
  • Tremel F, Caravel J P, Siche J P, Chevallier M, Mallion J M. Diagnostic value of renal scintigraphy with MAG 3 and DTPA in the diagnosis of renal artery stenosis. Arch Mal Coeur Vaiss 1996; 89: 1035–1039, [INFOTRIEVE], [CSA]
  • Kaplan-Pavlovcic S, Nadja C. Captopril renography and duplex Doppler sonography in the diagnosis of renovascular hypertension. Nephrol Dial Transplant 1998; 13: 313–317, [INFOTRIEVE], [CSA]
  • Gezici A, Ersay A, Antevska E, Heidental G K, Schreij G, Demirtas O C. Quantitative residual cortical activity measurement: appropriate test for diagnosis of renal artery stenosis?. Urol Int 1999; 62: 1–7, [INFOTRIEVE], [CROSSREF], [CSA]
  • Bongers V, Bakker J, Beutler J J, Beek F J, De Klerk J M. Assessment of renal artery stenosis: comparison of captopril renography and gadolinium-enhanced breath-hold MR angiography. Clin Radiol 2000; 55: 346–353, [INFOTRIEVE], [CROSSREF], [CSA]
  • Postma C T, van Aalen J, de Boo T, Rosenbusch G, Thien T. Doppler ultrasound scanning in the detection of renal artery stenosis in hypertensive patients. Br J Radiol 1992; 65: 857–860, [INFOTRIEVE], [CSA]
  • Miralles M, Santiso A, Gimenez A, Riambau V, Saez A, Daumal J, Cairols M A. Renal duplex scanning: correlation with angiography and isotopic renography. Eur J Vasc Surg 1993; 7: 188–194, [INFOTRIEVE], [CROSSREF], [CSA]
  • Kliewer M A, Tupler R H, Carroll B A, Paine S S, Kriegshauser J S, Hertzberg B S, Svetkey L P. Renal artery stenosis: analysis of Doppler waveform parameters and tardus-parvus pattern. Radiology 1993; 189: 779–787, [INFOTRIEVE], [CSA]
  • Olin J W, Piedmonte M R, Young J R, DeAnna S, Grubb M, Childs M B. The utility of duplex ultrasound scanning of the renal arteries for diagnosing significant renal artery stenosis. Ann Intern Med 1995; 122: 833–838, [INFOTRIEVE], [CSA]
  • Spies K P, Fobbe F, El Bedewi M, Wolf K J, Distler A, Schulte K L. Color-coded duplex sonography for noninvasive diagnosis and grading of renal artery stenosis. Am J Hypertens 1995; 8: 1222–1231, [INFOTRIEVE], [CROSSREF], [CSA]
  • Strotzer M, Fellner C M, Geissler A, Gmeinwieser J, Kohler S M, Kramer B K, Kromer E P. Noninvasive assessment of renal artery stenosis. A comparison of MR angiography, color Doppler sonography, and intraarterial angiography. Acta Radiol 1995; 36: 243–247, [INFOTRIEVE], [CSA]
  • Strunk H, Jaeger U. Duplex ultrasonographic diagnosis of renal artery stenosis by intrarenal acceleration determination and recognition of the tardus-parvus phenomenon with special regard to multiple renal arteries. Rofo 1995; 162: 420–428, [INFOTRIEVE], [CSA]
  • Lucas P, Blome S, Roche J. Intra-renal Doppler wave-form analysis as a screening test for renal artery stenosis. Australas Radiol 1996; 40: 276–282, [INFOTRIEVE], [CSA]
  • Postma C T, Bijlstra P J, Rosenbusch G, Thien T. Pattern recognition of loss of early systolic peak by Doppler ultrasound has a low sensitivity for the detection of renal artery stenosis. J Hum Hypertens 1996; 10: 181–184, [INFOTRIEVE], [CSA]
  • Miralles M, Cairols M, Cotillas J, Gimenez A, Santiso A. Value of Doppler parameters in the diagnosis of renal artery stenosis. J Vasc Surg 1996; 23: 428–435, [INFOTRIEVE], [CROSSREF], [CSA]
  • Vigna C, Pacilli M A, Testa M, Langialonga T, Salvatori M P, Lanna P, Russo A, Perna G P, Fanelli R, Loperfido F. Comparison of steerable continuous-wave versus pulsed-wave Doppler ultrasonography to renal artery angiography in diagnosing renal artery stenosis. Am J Cardiol 1998; 81: 365–367, [INFOTRIEVE], [CROSSREF], [CSA]
  • Oliva V L, Soulez G, Lesage D, Nicolet V, Roy M C, Courteau M, Froment D, Rene P C, Therasse E, Carignan L. Detection of renal artery stenosis with Doppler sonography before and after administration of captopril: value of early systolic rise. AJR Am J Roentgenol 1998; 170: 169–175, [INFOTRIEVE], [CSA]
  • Galanski M, Prokop M, Chavan A, Schaefer C, Jandeleit K, Olbricht C. Accuracy of CT angiography in the diagnosis of renal artery stenosis. Rofo 1994; 161: 519–25, [INFOTRIEVE], [CSA]
  • Olbricht C J, Paul K, Prokop M, Chavan A, Schaefer-Prokop C M, Jandeleit K, Koch K M, Galanski M. Minimally invasive diagnosis of renal artery stenosis by spiral computed tomography angiography. Kidney Int 1995; 48: 1332–1337, [INFOTRIEVE], [CSA]
  • Kaatee R, Beek F J, de Lange E E, van Leeuwen M S, Smits H F, van der Ven P J, Beutler J J, Mali W P. Renal artery stenosis: detection and quantification with spiral CT angiography versus optimized digital subtraction angiography. Radiology 1997; 205: 121–127, [INFOTRIEVE], [CSA]
  • Equine O, Beregi J P, Mounier-Vehier C, Gautier C, Desmoucelles F, Carre A. Importance of the echo-doppler and helical angioscanner of the renal arteries in the management of renovascular diseases. Results of a retrospective study in 113 patients. Arch Mal Coeur Vaiss 1999; 92: 1043–1045, [INFOTRIEVE], [CSA]
  • Postma C T, Joosten F B, Rosenbusch G, Thien T. Magnetic resonance angiography has a high reliability in the detection of renal artery stenosis. Am J Hypertens 1997; 10: 957–963, [INFOTRIEVE], [CROSSREF], [CSA]
  • Leung D A, Pelkonen P, Hany T F, Zimmermann G, Pfammatter T, Debatin J F. Value of image subtraction in 3D gadolinium-enhanced MR angiography of the renal arteries. J Magn Reson Imaging 1998; 8: 598–602, [INFOTRIEVE], [CSA]
  • Thornton J, O'Callaghan J, Walshe J, O'Brien E, Varghese J C, Lee M J. Comparison of digital subtraction angiography with gadolinium-enhanced magnetic resonance angiography in the diagnosis of renal artery stenosis. Eur Radiol 1999; 9: 930–934, [INFOTRIEVE], [CROSSREF], [CSA]
  • De Cobelli F, Venturini M, Vanzulli A, Sironi S, Salvioni M, Angeli E, Scifo P, Garancini M P, Quartagno R, Bianchi G, Del Maschio A. Renal arterial stenosis: prospective comparison of color Doppler US and breath-hold, three-dimensional, dynamic, gadolinium-enhanced MR angiography. Radiology 2000; 214: 373–380, [INFOTRIEVE], [CSA]
  • Korst M B, Joosten F B, Postma C T, Jager G J, Krabbe J K, Barentsz J O. Accuracy of normal-dose contrast-enhanced MR angiography in assessing renal artery stenosis and accessory renal arteries. AJR Am J Roentgenol 2000; 174: 629–634, [INFOTRIEVE], [CSA]
  • Goldblatt H. Hypertension of renal origin. Historical and experimental background. Am J Surg 1964; 107: 21–25, [INFOTRIEVE], [CROSSREF], [CSA]
  • Martinez-Maldonado M. Pathophysiology of renovascular hypertension. Hypertension 1991; 17: 707–719, [INFOTRIEVE], [CSA]
  • Doyle A E, Duffy S G. Sodium balance and plasma renin activity during the development of two-kidney Goldblatt hypertension in rats. Clin Exp Pharmacol Physiol 1980; 7: 293–304, [INFOTRIEVE], [CSA]
  • Pessina A C, Rossi G P. Real vein renin. Encyclopedia of Endocrine Diseases, L Martini. Academic Press, Elsevier Inc., Oxford 2004; 198–203
  • Welch W J. The pathophysiology of renin release in renovascular hypertension. Semin Nephrol 2000; 20: 394–401, [INFOTRIEVE], [CSA]
  • Laragh J H, Baer L, Brunner H R, Buhler F R, Sealey J E, Vaughan E D, Jr. Renin, angiotensin and aldosterone system in pathogenesis and management of hypertensive vascular disease. Am J Med 1972; 52: 633–652, [INFOTRIEVE], [CROSSREF], [CSA]
  • Case D B, Laragh J H. Reactive hyperreninemia in renovascular hypertension after angiotensin blockage with saralasin or converting enzyme inhibitor. Ann Intern Med 1979; 91: 153–160, [INFOTRIEVE], [CSA]
  • Rossi G, Semplicini A, Pessina A C, Perissinotto F, De Toni R, Feltrin G, Mozzato M G, Dal Palu C. Dynamic evaluation of the renin-angiotensin system with captopril in screening for renovascular hypertension. G Ital Cardiol 1985; 15: 472–477, [INFOTRIEVE], [CSA]
  • Radermacher J, Haller H. The right diagnostic work-up: investigating renal and renovascular disorders. J Hypertens Suppl 2003; 21: S19–S24, [INFOTRIEVE], [CROSSREF], [CSA]
  • Rossi G P, Bernini G, Caliumi C, Desideri G B, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello M J, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina A C, Mantero F, PAPY Study Investigators. A Prospective Study of The Prevalence of Primary Aldosteronism in 1125 Hypertensive Patients. J Am Coll Cardiol 2006, in press, [CSA]
  • Davidson R A, Wilcox C S. Newer tests for the diagnosis of renovascular disease. JAMA 1992; 268: 3353–3358, [INFOTRIEVE], [CROSSREF], [CSA]
  • Elliott W J, Martin W B, Murphy M B. Comparison of two noninvasive screening tests for renovascular hypertension. Arch Intern Med 1993; 153: 755–764, [INFOTRIEVE], [CROSSREF], [CSA]
  • Bijlstra P J, Postma C T, de Boo T, Thien T. Clinical and biochemical criteria in the detection of renal artery stenosis. J Hypertens 1996; 14: 1033–1040, [INFOTRIEVE], [CROSSREF], [CSA]
  • Pickering T G, Sos T A, Vaughan E D, Jr., Case D B, Sealey J E, Harshfield G A, Laragh J H. Predictive value and changes of renin secretion in hypertensive patients with unilateral renovascular disease undergoing successful renal angioplasty. Am J Med 1984; 76: 398–404, [INFOTRIEVE], [CROSSREF], [CSA]
  • Wilcox C S. Functional testing: renin studies. Semin Nephrol 2000; 20: 432–436, [INFOTRIEVE], [CSA]
  • Rossi G P, Cesari M, Chiesura-Corona M, Miotto D, Semplicini A, Pessina A C. Renal vein renin measurements accurately identify renovascular hypertension caused by total occlusion of the renal artery. J Hypertens 2002; 20: 975–984, [INFOTRIEVE], [CROSSREF], [CSA]
  • Webb D J, Cumming A M, Adams F C, Hodsman G P, Leckie B J, Lever A F, Morton J J, Murray G D, Robertson J I. Changes in active and inactive renin and in angiotensin II across the kidney in essential hypertension and renal artery stenosis. J Hypertens 1984; 2: 605–614, [INFOTRIEVE], [CROSSREF], [CSA]
  • Mann S J, Pickering T G. Detection of renovascular hypertension. State of the art: 1992. Ann Intern Med 1992; 117: 845–853, [INFOTRIEVE], [CSA]
  • Semple P F, Dominiczak A F. Detection and treatment of renovascular disease: 40 years on. J Hypertens 1994; 12: 729–734, [INFOTRIEVE], [CROSSREF], [CSA]
  • Pickering T G, Sos T A, Vaughan E D, Jr., Laragh J H. Differing patterns of renal vein renin secretion in patients with renovascular hypertension, and their role in predicting the response to angioplasty. Nephron 1986; 44(Suppl 1)8–11, [INFOTRIEVE], [CSA]
  • Hasbak P, Jensen L T, Ibsen H. Hypertension and renovascular disease: follow-up on 100 renal vein renin samplings. J Hum Hypertens 2002; 16: 275–280, [INFOTRIEVE], [CROSSREF], [CSA]
  • Rossi G P, Zanin L, Dessi-Fulgheri P, Savastano S, Cavazzana A, Prayer-Galetti T, Rappelli A, Pessina A C. A renin-secreting tumour with severe hypertension and cardiovascular disease: a diagnostic and therapeutic challenge. Clin Exp Hypertens 1993; 15: 325–338, [INFOTRIEVE], [CSA]
  • Radermacher J, Chavan A, Bleck J, Vitzthum A, Stoess B, Gebel M J, Galanski M, Koch K M, Haller H. Use of Doppler ultrasonography to predict the outcome of therapy for renal-artery stenosis. N Engl J Med 2001; 344: 410–417, [INFOTRIEVE], [CROSSREF], [CSA]
  • Textor S C, Wilcox C S. Renal artery stenosis: a common, treatable cause of renal failure?. Annu Rev Med 2001; 52: 421–442, [INFOTRIEVE], [CROSSREF], [CSA]
  • Bardelli M, Jensen G, Volkmann R, Aurell M. Non-invasive ultrasound assessment of renal artery stenosis by means of the Gosling pulsatility index. J Hypertens 1992; 10: 985–989, [INFOTRIEVE], [CROSSREF], [CSA]
  • Eley J D, Kelly J H. Importance of incubation conditions in measuring renin activity. Clin Chem 1977; 23: 1944–1945, [INFOTRIEVE], [CSA]
  • Roding J H, Weterings T, van der H C. Plasma renin activity: temperature optimum at approximately 45 degrees C. Clin Chem 1997; 43: 1243–1244, [INFOTRIEVE], [CSA]
  • Emanuel R L, Williams G H. Should blood samples for assay of plasma renin activity be chilled?. Clin Chem 1978; 24: 2042–2043, [INFOTRIEVE], [CSA]
  • Fyhrquist F, Puutula L. Effect of temperature on plasma renin samples. Clin Chem 1978; 24: 1202–1204, [INFOTRIEVE], [CSA]
  • Millar J A, Leckie B J, Morton J J, Jordan J, Tree M. A microassay for active and total renin concentration in human plasma based on antibody trapping. Clin Chim Acta 1980; 101: 5–15, [INFOTRIEVE], [CROSSREF], [CSA]
  • Roulston J E, Sanger B, Wathen C G. The stability of angiotensin I formed at room temperature in the presence of ethylenediaminetetraacetate to subsequent incubation at 37 degrees C. J Clin Chem Clin Biochem 1983; 21: 703–707, [INFOTRIEVE], [CSA]
  • Stirati G, de Martino A, Mene P, Pierucci A, Simonetti B M, Feriozzi S, Manzi M, Cinotti G A. Plasma renin activity: effect of temperature during blood processing. J Clin Chem Clin Biochem 1983; 21: 529–531, [INFOTRIEVE], [CSA]
  • Nussberger J, Brunner D B, Waeber B, Brunner H R. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II. Life Sci 1988; 42: 1683–1688, [INFOTRIEVE], [CROSSREF], [CSA]
  • Sealey J E. Plasma renin activity and plasma prorenin assays. Clin Chem 1991; 37: 1811–1819, [INFOTRIEVE], [CSA]
  • Bangham D R, Robertson I, Robertson J I, Robinson C J, Tree M. An international collaborative study of renin assay: establishment of the international reference preparation of human renin. Clin Sci Mol Med Suppl 1975; 2: 135a–159s, [INFOTRIEVE], [CSA]
  • Menard J, Guyenne T T, Corvol P, Pau B, Simon D, Roncucci R. Direct immunometric assay of active renin in human plasma. J Hypertens Suppl 1985; 3: S275–S278, [INFOTRIEVE], [CROSSREF], [CSA]
  • Derkx F H, de Bruin R J, van Gool J M, van den Hoek M J, Beerendonk C C, Rosmalen F, Haima P, Schalekamp M A. Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clin Chem 1996; 42: 1051–1063, [INFOTRIEVE], [CSA]
  • Piffanelli A, Morganti A, Mantero F, Cianetti A, Zucchelli G C, Giovannini G, Pelizzola D. Supraregional interlaboratory quality-control survey for an immunoradiometric renin assay. Clin Chem 2001; 47: 2148–2150, [INFOTRIEVE], [CSA]
  • Arnal J F, Cudek P, Plouin P F, Guyenne T T, Michel J B, Corvol P. Low angiotensinogen levels are related to the severity and liver dysfunction of congestive heart failure: implications for renin measurements 1. Am J Med 1991; 90: 17–22, [INFOTRIEVE], [CROSSREF], [CSA]
  • Deinum J, Derkx F H, Schalekamp M A. Improved immunoradiometric assay for plasma renin. Clin Chem 1999; 45: 847–854, [INFOTRIEVE], [CSA]
  • Simon D, Hartmann D J, Badouaille G, Caillot G, Guyenne T T, Corvol P, Pau B, Marchand J. Two-site direct immunoassay specific for active renin. Clin Chem 1992; 38: 1959–1962, [INFOTRIEVE], [CSA]
  • Sealey J E, Atlas S A, Laragh J H. Prorenin and other large molecular weight forms of renin. Endocr Rev 1980; 1: 365–391, [INFOTRIEVE], [CSA]
  • Derkx F H, Schalekamp M A. Human prorenin: pathophysiology and clinical implications. Clin Exp Hypertens A 1988; 10: 1213–325, [INFOTRIEVE], [CSA]
  • Nielsen A H, Poulsen K. Is prorenin of physiological and clinical significance?. J Hypertens 1988; 6: 949–958, [INFOTRIEVE], [CROSSREF], [CSA]
  • Sealey J E, Laragh J H. Renin and prorenin: advances and declines in methodology. Clin Chem 1996; 42: 993–994, [INFOTRIEVE], [CSA]
  • Morganti A, Pelizzola D, Mantero F, Gazzano G, Opocher G, Piffanelli A. Immunoradiometric versus enzymatic renin assay: results of the Italian Multicenter Comparative Study. Italian Multicenter Study for Standardization of Renin Measurement. J Hypertens 1995; 13: 19–26, [INFOTRIEVE], [CROSSREF], [CSA]
  • de Bruin R A, Bouhuizen A, Diederich S, Perschel F H, Boomsma F, Deinum J. Validation of a new automated renin assay. Clin Chem 2004; 50: 2111–2116, [INFOTRIEVE], [CROSSREF], [CSA]
  • Blumenfeld J D, Sealey J E, Schlussel Y, Vaughan E D, Jr., Sos T A, Atlas S A, Muller F B, Acevedo R, Ulick S, Laragh J H. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877–885, [INFOTRIEVE], [CSA]
  • Fredline V F, Kovacs E M, Taylor P J, Johnson A G. Measurement of plasma renin activity with use of HPLC-electrospray-tandem mass spectrometry. Clin Chem 1999; 45: 659–664, [INFOTRIEVE], [CSA]
  • Nussberger J, Brunner D B, Waeber B, Brunner H R. True versus immunoreactive angiotensin II in human plasma. Hypertension 1985; 7: I1–I7, [INFOTRIEVE], [CSA]
  • Souther M E, Lumpkin R H, Kuo K C, Reams G P, Bauer J H, Gehrke C W. High-performance liquid chromatographic-radioimmunoassay method for the measurement of angiotensin II peptides in human plasma. J Chromatogr 1987; 417: 27–40, [INFOTRIEVE], [CSA]
  • Kawamura M, Yoshida K, Akabane S, Matsushima Y, Kawano Y, Kojima S, Takahashi N, Shimamoto K, Ito K, Omae T. A sensitive method for precise measurement of endogenous angiotensins I, II&III in human plasma. Clin Exp Hypertens A 1987; 9: 687–691, [INFOTRIEVE], [CSA]
  • Hermann K, Ganten D, Unger T, Bayer C, Lang R E. Measurement and characterization of angiotensin peptides in plasma. Clin Chem 1988; 34: 1046–1051, [INFOTRIEVE], [CSA]
  • Huang H, Baussant T, Reade R, Michel J B, Corvol P. Measurement of angiotensin II concentration in rat plasma: pathophysiological applications. Clin Exp Hypertens A 1989; 11: 1535–1548, [INFOTRIEVE], [CSA]
  • Hanssens M, Keirse M J, Lijnen P J, Kucharski M J, Luyten C, Van Assche F A. Measurement of individual angiotensin peptides by HPLC-RIA. J Biochem Biophys Methods 1990; 21: 103–113, [INFOTRIEVE], [CROSSREF], [CSA]
  • Hermann K, Ring J, Phillips M I. High-performance liquid chromatography for the separation of angiotensin and its metabolites in human plasma and sweat. J Chromatogr Sci 1990; 28: 524–528, [INFOTRIEVE], [CSA]
  • Campbell D J, Kladis A. Simultaneous radioimmunoassay of six angiotensin peptides in arterial and venous plasma of man. J Hypertens 1990; 8: 165–172, [INFOTRIEVE], [CROSSREF], [CSA]
  • Simon D, Romestand B, Huang H, Badouaille G, Fehrentz J A, Pau B, Marchand J, Corvol P. Direct, simplified, and sensitive assay of angiotensin II in plasma extracts performed with a high-affinity monoclonal antibody. Clin Chem 1992; 38: 1963–1967, [INFOTRIEVE], [CSA]
  • Stewart P M. The adrenal cortex. Williams Textbook of Endocrinology, 10th Ed., P R Larsen, H M Kronenberg, S Melmed, K S Polonski. Saunders, Philadelphia 2003; 491–551
  • Orth D N. Cushing's syndrome. N Engl J Med 1995; 332: 791–803, [INFOTRIEVE], [CROSSREF], [CSA]
  • Newell-Price J, Trainer P, Besser M, Grossman A. The diagnosis and differential diagnosis of Cushing's syndrome and pseudo-Cushing's states. Endocr Rev 1998; 19: 647–672, [INFOTRIEVE], [CROSSREF], [CSA]
  • Nieman L K. Diagnostic tests for Cushing's syndrome. Ann NY Acad Sci 2002; 970: 112–118, [INFOTRIEVE], [CSA]
  • Crapo L. Cushing's syndrome: a review of diagnostic tests. Metabolism 1979; 28: 955–977, [INFOTRIEVE], [CROSSREF], [CSA]
  • Arnaldi G, Angeli A, Atkinson A B, Bertagna X, Cavagnini F, Chrousos G P, Fava G A, Findling J W, Gaillard R C, Grossman A B, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman L K, Sonino N, Vance M L, Giustina A, Boscaro M. Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003; 88: 5593–5602, [INFOTRIEVE], [CROSSREF], [CSA]
  • Bolufer P, Gandia A, Rodriguez A, Antonio P. Salivary corticosteroids in the study of adrenal function. Clin Chim Acta 1989; 183: 217–225, [INFOTRIEVE], [CROSSREF], [CSA]
  • Newell-Price J, Trainer P, Perry L, Wass J, Grossman A, Besser M. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1995; 43: 545–550, [CSA]
  • Raff H, Raff J L, Findling J W. Late-night salivary cortisol as a screening test for Cushing's syndrome. J Clin Endocrinol Metab 1998; 83: 2681–2686, [INFOTRIEVE], [CROSSREF], [CSA]
  • Castro M, Elias P C, Quidute A R, Halah F P, Moreira A C. Out-patient screening for Cushing's syndrome: the sensitivity of the combination of circadian rhythm and overnight dexamethasone suppression salivary cortisol tests. J Clin Endocrinol Metab 1999; 84: 878–882, [INFOTRIEVE], [CROSSREF], [CSA]
  • Yaneva M, Mosnier-Pudar H, Dugue M A, Grabar S, Fulla Y, Bertagna X. Midnight salivary cortisol for the initial diagnosis of Cushing's syndrome of various causes. J Clin Endocrinol Metab 2004; 89: 3345–3351, [INFOTRIEVE], [CROSSREF], [CSA]
  • Viardot A, Huber P, Puder J J, Zulewski H, Keller U, Muller B. Reproducibility of nighttime salivary cortisol and its use in the diagnosis of hypercortisolism compared with urinary free cortisol and overnight dexamethasone suppression test. J Clin Endocrinol Metab 2005; 90: 5730–5736, [INFOTRIEVE], [CROSSREF], [CSA]
  • Flack M R, Oldfield E H, Cutler G B, Jr., Zweig M H, Malley J D, Chrousos G P, Loriaux D L, Nieman L K. Urine free cortisol in the high-dose dexamethasone suppression test for the differential diagnosis of the Cushing syndrome. Ann Intern Med 1992; 116: 211–217, [INFOTRIEVE], [CSA]
  • Miller J L. MIS priorities for MSO's (management services organization) & clinics without walls. Integr Healthc Rep Jan, 1994; 7–9, [CSA]
  • McMahon G T, Dluhy R G. Glucocorticoid-remediable aldosteronism. Arq Bras Endocrinol Metabol 2004; 48: 682–686, [INFOTRIEVE], [CSA]
  • Lifton R P, Gharavi A G, Geller D S. Molecular mechanisms of human hypertension. Cell 2001; 104: 545–556, [INFOTRIEVE], [CROSSREF], [CSA]
  • New M I, Geller D S, Fallo F, Wilson R C. Monogenic low renin hypertension. Trends Endocrinol Metab 2005; 16: 92–97, [INFOTRIEVE], [CROSSREF], [CSA]
  • Mulatero P, Veglio F, Pilon C, Rabbia F, Zocchi C, Limone P, Boscaro M, Sonino N, Fallo F. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene. J Clin Endocrinol Metab 1998; 83: 2573–2575, [INFOTRIEVE], [CROSSREF], [CSA]
  • Gordon R D, Stowasser M, Tunny T J, Klemm S A, Finn W L, Krek A L. Clinical and pathological diversity of primary aldosteronism, including a new familial variety. Clin Exp Pharmacol Physiol 1991; 18: 283–286, [INFOTRIEVE], [CSA]
  • Stowasser M, Gordon R D. Familial hyperaldosteronism. J Steroid Biochem Mol Biol 2001; 78: 215–229, [INFOTRIEVE], [CSA]
  • Luft F C. Mendelian forms of human hypertension and mechanisms of disease. Clin Med Res 2003; 1: 291–300, [INFOTRIEVE], [CSA]
  • Mein C A, Caulfield M J, Dobson R J, Munroe P B. Genetics of essential hypertension. Hum Mol Genet 2004; 13: R169–R175, Spec No 1[INFOTRIEVE], [CROSSREF], [CSA]
  • Wilson F H, Disse-Nicodeme S, Choate K A, Ishikawa K, Nelson-Williams C, Desitter I, Gunel M, Milford D V, Lipkin G W, Achard J M, Feely M P, Dussol B, Berland Y, Unwin R J, Mayan H, Simon D B, Farfel Z, Jeunemaitre X, Lifton R P. Human hypertension caused by mutations in WNK kinases. Science 2001; 293: 1107–1112, [INFOTRIEVE], [CROSSREF], [CSA]
  • Ulick S, Levine L S, Gunczler P, Zanconato G, Ramirez L C, Rauh W, Rosler A, Bradlow H L, New M I. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. J Clin Endocrinol Metab 1979; 49: 757–764, [INFOTRIEVE], [CSA]
  • Stewart P M, Corrie J E, Shackleton C H, Edwards C R. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. J Clin Invest 1988; 82: 340–349, [INFOTRIEVE], [CSA]
  • Edwards C R, Stewart P M, Burt D, Brett L, McIntyre M A, Sutanto W S, de Kloet E R, Monder C. Localisation of 11 beta-hydroxysteroid dehydrogenase–tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 2: 986–989, [INFOTRIEVE], [CROSSREF], [CSA]
  • Funder J W, Pearce P T, Smith R, Smith A I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science 1988; 242: 583–585, [INFOTRIEVE], [CROSSREF], [CSA]
  • Wilson R C, Krozowski Z S, Li K, Obeyesekere V R, Razzaghy-Azar M, Harbison M D, Wei J Q, Shackleton C H, Funder J W, New M I. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1995; 80: 2263–2266, [INFOTRIEVE], [CROSSREF], [CSA]
  • Mune T, Rogerson F M, Nikkila H, Agarwal A K, White P C. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nat Genet 1995; 10: 394–399, [INFOTRIEVE], [CROSSREF], [CSA]
  • Stewart P M, Krozowski Z S, Gupta A, Milford D V, Howie A J, Sheppard M C, Whorwood C B. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet 1996; 347: 88–91, [INFOTRIEVE], [CROSSREF], [CSA]
  • Monder C, Shackleton C H, Bradlow H L, New M I, Stoner E, Iohan F, Lakshmi V. The syndrome of apparent mineralocorticoid excess: its association with 11 beta-dehydrogenase and 5 beta-reductase deficiency and some consequences for corticosteroid metabolism. J Clin Endocrinol Metab 1986; 63: 550–557, [INFOTRIEVE], [CSA]
  • Luft F C. Molecular genetics of salt-sensitivity and hypertension. Drug Metab Dispos 2001; 29: 500–504, [INFOTRIEVE], [CSA]
  • Stewart P M, Wallace A M, Valentino R, Burt D, Shackleton C H, Edwards C R. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987; 2: 821–824, [INFOTRIEVE], [CROSSREF], [CSA]
  • Farese R V, Jr., Biglieri E G, Shackleton C H, Irony I, Gomez-Fontes R. Licorice-induced hypermineralocorticoidism. N Engl J Med 1991; 325: 1223–1227, [INFOTRIEVE], [CSA]
  • Canessa C M, Schild L, Buell G, Thorens B, Gautschi I, Horisberger J D, Rossier B C. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 1994; 367: 463–467, [INFOTRIEVE], [CROSSREF], [CSA]
  • Shimkets R A, Warnock D G, Bositis C M, Nelson-Williams C, Hansson J H, Schambelan M, Gill J R, Jr., Ulick S, Milora R V, Findling J W. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79: 407–414, [INFOTRIEVE], [CROSSREF], [CSA]
  • Hansson J H, Nelson-Williams C, Suzuki H, Schild L, Shimkets R, Lu Y, Canessa C, Iwasaki T, Rossier B, Lifton R P. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 1995; 11: 76–82, [INFOTRIEVE], [CROSSREF], [CSA]
  • Hansson J H, Schild L, Lu Y, Wilson T A, Gautschi I, Shimkets R, Nelson-Williams C, Rossier B C, Lifton R P. A de novo missense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci USA 1995; 92: 11495–11499, [INFOTRIEVE], [CROSSREF], [CSA]
  • Botero-Velez M, Curtis J J, Warnock D G. Brief report: Liddle's syndrome revisited—a disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994; 330: 178–181, [INFOTRIEVE], [CROSSREF], [CSA]
  • Persu A, Barbry P, Bassilana F, Houot A M, Mengual R, Lazdunski M, Corvol P, Jeunemaitre X. Genetic analysis of the beta subunit of the epithelial Na+ channel in essential hypertension. Hypertension 1998; 32: 129–137, [INFOTRIEVE], [CSA]
  • Hummler E, Horisberger J D. Genetic disorders of membrane transport. V. The epithelial sodium channel and its implication in human diseases. Am J Physiol 1999; 276: G567–G571, [INFOTRIEVE], [CSA]
  • Blythe W B. Natural history of hypertension in renal parenchymal disease. Am J Kidney Dis 1985; 5: A50–A56, [INFOTRIEVE], [CSA]
  • Martinez-Maldonado M. Role of hypertension in the progression of chronic renal disease. Nephrol Dial Transplant 2001; 16(Suppl 1)63–66, [INFOTRIEVE], [CSA]
  • Whitworth J A. Progression of renal failure—the role of hypertension. Ann Acad Med Singapore 2005; 34: 8–15, [INFOTRIEVE], [CSA]
  • K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39: S1–266, [CROSSREF], [CSA]
  • Abbott K C, Trespalacios F C, Welch P G, Agodoa L Y. Scleroderma at end stage renal disease in the United States: patient characteristics and survival. J Nephrol 2002; 15: 236–240, [INFOTRIEVE], [CROSSREF], [CSA]
  • Steen V D. Scleroderma renal crisis. Rheum Dis Clin North Am 2003; 29: 315–333, [INFOTRIEVE], [CROSSREF], [CSA]
  • O'Callaghan C A. Renal manifestations of systemic autoimmune disease: diagnosis and therapy. Best Pract Res Clin Rheumatol 2004; 18: 411–427, [INFOTRIEVE], [CSA]
  • First M R. Tacrolimus based immunosuppression. J Nephrol 2004; 17(Suppl 8)S25–S31, [INFOTRIEVE], [CSA]
  • Sinclair A M, Isles C G, Brown I, Cameron H, Murray G D, Robertson J W. Secondary hypertension in a blood pressure clinic. Arch Intern Med 1987; 147: 1289–1293, [INFOTRIEVE], [CROSSREF], [CSA]
  • Salem M M. Hypertension in the hemodialysis population: a survey of 649 patients. Am J Kidney Dis 1995; 26: 461–468, [INFOTRIEVE], [CSA]
  • Rocco M V, Yan G, Heyka R J, Benz R, Cheung A K. Risk factors for hypertension in chronic hemodialysis patients: baseline data from the HEMO study. Am J Nephrol 2001; 21: 280–288, [INFOTRIEVE], [CROSSREF], [CSA]
  • Agarwal R, Nissenson A R, Batlle D, Coyne D W, Trout J R, Warnock D G. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med 2003; 115: 291–297, [INFOTRIEVE], [CROSSREF], [CSA]
  • Agarwal R. Hypertension and survival in chronic hemodialysis patients–past lessons and future opportunities. Kidney Int 2005; 67: 1–13, [INFOTRIEVE], [CROSSREF], [CSA]
  • Hernandez D, Alvarez A, Torres A, Oppenheimer F, Cobo M, Gonzalez-Posada J, Jimenez A, Lorenzo V, Torregrosa V. Cardiovascular risk profile in nondiabetic renal transplant patients: cyclosporine versus tacrolimus. Transplant Proc 2003; 35: 1727–1729, [INFOTRIEVE], [CROSSREF], [CSA]
  • Margreiter R, Pohanka E, Sparacino V, Sperschneider H, Kunzendorf U, Huber W, Lameire N, Andreucci V E, Donati D, Heemann U. Open prospective multicenter study of conversion to tacrolimus therapy in renal transplant patients experiencing ciclosporin-related side-effects. Transpl Int 2005; 18: 816–823, [INFOTRIEVE], [CROSSREF], [CSA]
  • Newstead C G. Recurrent disease in renal transplants. Nephrol Dial Transplant 2003; 18(Suppl 6)vi68–vi74, [INFOTRIEVE], [CSA]
  • Perrone R D, Steinman T I, Beck G J, Skibinski C I, Royal H D, Lawlor M, Hunsicker L G. Utility of radioisotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 169Yb-DTPA, 99mTc-DTPA, and inulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 1990; 16: 224–235, [INFOTRIEVE], [CSA]
  • Walser M. Assessing renal function from creatinine measurements in adults with chronic renal failure. Am J Kidney Dis 1998; 32: 23–31, [INFOTRIEVE], [CSA]
  • Cockcroft D W, Gault M H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41, [INFOTRIEVE], [CSA]
  • Gault M H, Longerich L L, Harnett J D, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron 1992; 62: 249–256, [INFOTRIEVE], [CSA]
  • Levey A S, Bosch J P, Lewis J B, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461–470, [INFOTRIEVE], [CSA]
  • Lewis J, Agodoa L, Cheek D, Greene T, Middleton J, O'Connor D, Ojo A, Phillips R, Sika M, Wright J, Jr. Comparison of cross-sectional renal function measurements in African Americans with hypertensive nephrosclerosis and of primary formulas to estimate glomerular filtration rate. Am J Kidney Dis 2001; 38: 744–753, [INFOTRIEVE], [CSA]
  • Weitgasser R, Schnoell F, Gappmayer B, Kartnig I. Prospective evaluation of urinary N-acetyl-beta-D-glucosaminidase with respect to macrovascular disease in elderly type 2 diabetic patients. Diabetes Care 1999; 22: 1882–1886, [INFOTRIEVE], [CSA]
  • Schwab S J, Christensen R L, Dougherty K, Klahr S. Quantitation of proteinuria by the use of protein-to-creatinine ratios in single urine samples. Arch Intern Med 1987; 147: 943–944, [INFOTRIEVE], [CROSSREF], [CSA]
  • Ruggenenti P, Gaspari F, Perna A, Remuzzi G. Cross sectional longitudinal study of spot morning urine protein: creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ 1998; 316: 504–509, [INFOTRIEVE], [CSA]
  • Richards N T, Darby S, Howie A J, Adu D, Michael J. Knowledge of renal histology alters patient management in over 40% of cases. Nephrol Dial Transplant 1994; 9: 1255–1259, [INFOTRIEVE], [CSA]
  • Cohen A H, Nast C C, Adler S G, Kopple J D. Clinical utility of kidney biopsies in the diagnosis and management of renal disease. Am J Nephrol 1989; 9: 309–315, [INFOTRIEVE], [CSA]
  • Korbet S M. Percutaneous renal biopsy. Semin Nephrol 2002; 22: 254–267, [INFOTRIEVE], [CROSSREF], [CSA]
  • Fogo A B. Approach to renal biopsy. Am J Kidney Dis 2003; 42: 826–836, [INFOTRIEVE], [CROSSREF], [CSA]
  • Conn J W, Cohen E L, Lucas C P, McDonald W J, Mayor G H, Blough W M, Jr., Eveland W C, Bookstein J J, Lapides J. Primary reninism. Hypertension, hyperreninemia, and secondary aldosteronism due to renin-producing juxtaglomerular cell tumors. Arch Intern Med 1972; 130: 682–696, [INFOTRIEVE], [CSA]
  • Chambo J L, Falci J R, Lucon A M. Juxtaglomerular cell tumor as a rare cause of hypertension in adults. Int Braz J Urol 2004; 30: 119–120, [INFOTRIEVE], [CSA]
  • Saito I, Ito K, Saruta T. Hypothyroidism as a cause of hypertension. Hypertension 1983; 5: 112–115, [INFOTRIEVE], [CSA]
  • Fletcher A K, Weetman A P. Hypertension and hypothyroidism. J Hum Hypertens 1998; 12: 79–82, [INFOTRIEVE], [CROSSREF], [CSA]
  • Woeber K A. Update on the management of hyperthyroidism and hypothyroidism. Arch Fam Med 2000; 9: 743–747, [INFOTRIEVE], [CROSSREF], [CSA]
  • Marcisz C, Jonderko G, Kucharz E. Changes of arterial pressure in patients with hyperthyroidism during therapy. Med Sci Monit 2002; 8: CR502–CR507, [INFOTRIEVE], [CSA]
  • Dillmann W H. Biochemical basis of thyroid hormone action in the heart. Am J Med 1990; 88: 626–630, [INFOTRIEVE], [CROSSREF], [CSA]
  • Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501–509, [INFOTRIEVE], [CROSSREF], [CSA]
  • Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab 2002; 87: 1996–2000, [INFOTRIEVE], [CROSSREF], [CSA]
  • Dzau V J, Herrmann H C. Hormonal control of angiotensinogen production. Life Sci 1982; 30: 577–584, [INFOTRIEVE], [CROSSREF], [CSA]
  • Sergev O, Racz K, Varga I, Kiss R, Futo L, Mohari K, Glaz E. Thyrotropin-releasing hormone increases plasma atrial natriuretic peptide levels in human. J Endocrinol Invest 1990; 13: 649–652, [INFOTRIEVE], [CSA]
  • Hanna F W, Scanlon M F. Hyponatraemia, hypothyroidism, and role of arginine-vasopressin. Lancet 1997; 350: 755–756, [INFOTRIEVE], [CROSSREF], [CSA]
  • Montenegro J, Gonzalez O, Saracho R, Aguirre R, Gonzalez O, Martinez I. Changes in renal function in primary hypothyroidism. Am J Kidney Dis 1996; 27: 195–198, [INFOTRIEVE], [CSA]
  • Park K W, Dai H B, Ojamaa K, Lowenstein E, Klein I, Sellke F W. The direct vasomotor effect of thyroid hormones on rat skeletal muscle resistance arteries. Anesth Analg 1997; 85: 734–738, [INFOTRIEVE], [CROSSREF], [CSA]
  • Vanderpump M P, Tunbridge W M, French J M, Appleton D, Bates D, Clark F, Grimley E J, Hasan D M, Rodgers H, Tunbridge F. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol (Oxf) 1995; 43: 55–68, [CSA]
  • Toft A D, Boon N A. Thyroid disease and the heart. Heart 2000; 84: 455–460, [INFOTRIEVE], [CROSSREF], [CSA]
  • Hollowell J G, Staehling N W, Flanders W D, Hannon W H, Gunter E W, Spencer C A, Braverman L E. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 2002; 87: 489–499, [INFOTRIEVE], [CROSSREF], [CSA]
  • Streeten D H, Anderson G H, Jr., Howland T, Chiang R, Smulyan H. Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension. Hypertension 1988; 11: 78–83, [INFOTRIEVE], [CSA]
  • Cooper D S. Clinical practice. Subclinical hypothyroidism. N Engl J Med 2001; 345: 260–265, [INFOTRIEVE], [CROSSREF], [CSA]
  • Sahun M, Villabona C, Rosel P, Navarro M A, Ramon J M, Gomez J M, Soler J. Water metabolism disturbances at different stages of primary thyroid failure. J Endocrinol 2001; 168: 435–445, [INFOTRIEVE], [CROSSREF], [CSA]
  • Toft A D. Clinical practice. Subclinical hyperthyroidism. N Engl J Med 2001; 345: 512–516, [INFOTRIEVE], [CROSSREF], [CSA]
  • Luboshitzky R, Aviv A, Herer P, Lavie L. Risk factors for cardiovascular disease in women with subclinical hypothyroidism. Thyroid 2002; 12: 421–425, [INFOTRIEVE], [CROSSREF], [CSA]
  • Surks M I, Ortiz E, Daniels G H, Sawin C T, Col N F, Cobin R H, Franklyn J A, Hershman J M, Burman K D, Denke M A, Gorman C, Cooper R S, Weissman N J. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004; 291: 228–238, [INFOTRIEVE], [CROSSREF], [CSA]
  • Klein I, Levey G S. New perspectives on thyroid hormone, catecholamines, and the heart. Am J Med 1984; 76: 167–172, [INFOTRIEVE], [CROSSREF], [CSA]
  • Fraser R, Davies D L, Connell J M. Hormones and hypertension. Clin Endocrinol (Oxf) 1989; 31: 701–746, [CSA]
  • Wang H H. Reporting thyroid fine-needle aspiration: literature review and a proposal. Diagn Cytopathol 2006; 34: 67–76, [INFOTRIEVE], [CROSSREF], [CSA]
  • Khati N, Adamson T, Johnson K S, Hill M C. Ultrasound of the thyroid and parathyroid glands. Ultrasound Q 2003; 19: 162–176, [INFOTRIEVE], [CROSSREF], [CSA]
  • Stockigt J R. Case finding and screening strategies for thyroid dysfunction. Clin Chim Acta 2002; 315: 111–124, [INFOTRIEVE], [CROSSREF], [CSA]
  • Helfand M, Redfern C C. Clinical guideline, part 2. Screening for thyroid disease: an update. American College of Physicians. Ann Intern Med 1998; 129: 144–158, [INFOTRIEVE], [CSA]
  • Attia J, Margetts P, Guyatt G. Diagnosis of thyroid disease in hospitalized patients: a systematic review. Arch Intern Med 1999; 159: 658–665, [INFOTRIEVE], [CROSSREF], [CSA]
  • Kaplan M M. Clinical perspectives in the diagnosis of thyroid disease. Clin Chem 1999; 45: 1377–1383, [INFOTRIEVE], [CSA]
  • Garcia d lT, Wass J A, Turner H E. Parathyroid adenomas and cardiovascular risk. Endocr Relat Cancer 2003; 10: 309–322, [CROSSREF], [CSA]
  • Andersson P, Rydberg E, Willenheimer R. Primary hyperparathyroidism and heart disease–a review. Eur Heart J 2004; 25: 1776–1787, [INFOTRIEVE], [CROSSREF], [CSA]
  • Broulik P D, Horky K, Pacovsky V. Blood pressure in patients with primary hyperparathyroidism before and after parathyroidectomy. Exp Clin Endocrinol 1985; 86: 346–352, [INFOTRIEVE], [CSA]
  • Uden P, Chan A, Duh Q Y, Siperstein A, Clark O H. Primary hyperparathyroidism in younger and older patients: symptoms and outcome of surgery. World J Surg 1992; 16: 791–797, [INFOTRIEVE], [CROSSREF], [CSA]
  • Salahudeen A K, Thomas T H, Sellars L, Tapster S, Keavey P, Farndon J R, Johnston I D, Wilkinson R. Hypertension and renal dysfunction in primary hyperparathyroidism: effect of parathyroidectomy. Clin Sci (Lond) 1989; 76: 289–296, [CSA]
  • Sancho J J, Rouco J, Riera-Vidal R, Sitges-Serra A. Long-term effects of parathyroidectomy for primary hyperparathyroidism on arterial hypertension. World J Surg 1992; 16: 732–735, [INFOTRIEVE], [CROSSREF], [CSA]
  • Rodriguez-Portales J A, Fardella C. Primary hyperparathyroidism and hypertension: persistently abnormal pressor sensitivity in normotensive patients after surgical cure. J Endocrinol Invest 1994; 17: 307–311, [INFOTRIEVE], [CSA]
  • Younes N A, Shafagoj Y, Khatib F, Ababneh M. Laboratory screening for hyperparathyroidism. Clin Chim Acta 2005; 353: 1–12, [INFOTRIEVE], [CROSSREF], [CSA]
  • Gordon R D, Laragh J H, Funder J W. Low renin hypertensive states: perspectives, unsolved problems, future research. Trends Endocrinol Metab 2005; 16: 108–113, [INFOTRIEVE], [CROSSREF], [CSA]
  • Morales J M, Andres A, Rengel M, Rodicio J L. Influence of cyclosporin, tacrolimus and rapamycin on renal function and arterial hypertension after renal transplantation. Nephrol Dial Transplant 2001; 16(Suppl 1)121–124, [INFOTRIEVE], [CSA]
  • Busauschina A, Schnuelle P, van der Woude F J. Cyclosporine nephrotoxicity. Transplant Proc 2004; 36: 229S–33S, [INFOTRIEVE], [CROSSREF], [CSA]
  • Tilney N L, Milford E L, Araujo J L, Strom T B, Carpenter C B, Kirkman R L. Experience with cyclosporine and steroids in clinical renal transplantation. Ann Surg 1984; 200: 605–613, [INFOTRIEVE], [CROSSREF], [CSA]
  • Textor S C, Wiesner R, Wilson D J, Porayko M, Romero J C, Burnett J C, Jr., Gores G, Hay E, Dickson E R, Krom R A. Systemic and renal hemodynamic differences between FK506 and cyclosporine in liver transplant recipients. Transplantation 1993; 55: 1332–1339, [INFOTRIEVE], [CROSSREF], [CSA]
  • Mayer A D, Dmitrewski J, Squifflet J P, Besse T, Grabensee B, Klein B, Eigler F W, Heemann U, Pichlmayr R, Behrend M, Vanrenterghem Y, Donck J, van Hooff J, Christiaans M, Morales J M, Andres A, Johnson R W, Short C, Buchholz B, Rehmert N, Land W, Schleibner S, Forsythe J L, Talbot D, Pohanka E. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436–443, [INFOTRIEVE], [CROSSREF], [CSA]
  • Pirsch J D, Miller J, Deierhoi M H, Vincenti F, Filo R S. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977–983, [INFOTRIEVE], [CROSSREF], [CSA]
  • Kramer B K, Boger C, Kruger B, Marienhagen J, Pietrzyk M, Obed A, Paczek L, Mack M, Banas B. Cardiovascular risk estimates and risk factors in renal transplant recipients. Transplant Proc 2005; 37: 1868–1870, [INFOTRIEVE], [CROSSREF], [CSA]
  • Perico N, Dadan J, Remuzzi G. Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat. J Am Soc Nephrol 1990; 1: 76–83, [INFOTRIEVE], [CSA]
  • Morris S T, McMurray J J, Rodger R S, Farmer R, Jardine A G. Endothelial dysfunction in renal transplant recipients maintained on cyclosporine. Kidney Int 2000; 57: 1100–1106, [INFOTRIEVE], [CROSSREF], [CSA]
  • Ovuworie C A, Fox E R, Chow C M, Pascual M, Shih V E, Picard M H, Tolkoff-Rubin N E. Vascular endothelial function in cyclosporine and tacrolimus treated renal transplant recipients. Transplantation 2001; 72: 1385–1388, [INFOTRIEVE], [CROSSREF], [CSA]
  • Calò L A, Davis P A, Giacon B, Pagnin E, Sartori M, Riegler P, Antonello A, Huber W, Semplicini A. Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril. J Cardiovasc Pharmacol 2002; 40: 625–631, [CROSSREF], [CSA]
  • Scherrer U, Vissing S F, Morgan B J, Rollins J A, Tindall R S, Ring S, Hanson P, Mohanty P K, Victor R G. Cyclosporine-induced sympathetic activation and hypertension after heart transplantation. N Engl J Med 1990; 323: 693–699, [INFOTRIEVE], [CSA]
  • Nitta K, Friedman A L, Nicastri A D, Paik S, Friedman E A. Granular juxtaglomerular cell hyperplasia caused by cyclosporine. Transplantation 1987; 44: 417–421, [INFOTRIEVE], [CSA]
  • Pichler R H, Franceschini N, Young B A, Hugo C, Andoh T F, Burdmann E A, Shankland S J, Alpers C E, Bennett W M, Couser W G. Pathogenesis of cyclosporine nephropathy: roles of angiotensin II and osteopontin. J Am Soc Nephrol 1995; 6: 1186–1196, [INFOTRIEVE], [CSA]
  • Wong W, Tolkoff-Rubin N, Delmonico F L, Cardarelli F, Saidman S L, Farrell M L, Shih V, Winkelmayer W C, Cosimi A B, Pascual M. Analysis of the cardiovascular risk profile in stable kidney transplant recipients after 50% cyclosporine reduction. Clin Transplant 2004; 18: 341–348, [INFOTRIEVE], [CROSSREF], [CSA]
  • Tuncel M, Wang Z, Arbique D, Fadel P J, Victor R G, Vongpatanasin W. Mechanism of the blood pressure–raising effect of cocaine in humans. Circulation 2002; 105: 1054–1059, [INFOTRIEVE], [CROSSREF], [CSA]
  • Linder M W, Bosse G M, Henderson M T, Midkiff G, Valdes R. Detection of cocaine metabolite in serum and urine: frequency and correlation with medical diagnosis. Clin Chim Acta 2000; 295: 179–185, [INFOTRIEVE], [CROSSREF], [CSA]
  • Schramm W, Craig P A, Smith R H, Berger G E. Cocaine and benzoylecgonine in saliva, serum, and urine. Clin Chem 1993; 39: 481–487, [INFOTRIEVE], [CSA]
  • Phillips D L, Tebbett I R, Bertholf R L. Comparison of HPLC and GC-MS for measurement cocaine and metabolites in human urine. J Anal Toxicol 1996; 20: 305–308, [INFOTRIEVE], [CSA]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.